NASDAQ:NAMS | Free Cash Flow | NewAmsterdam Pharma Co N.V.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2021-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$30.6M
2025-12-31-$40.88M
2025-03-31-$36.47M
2024-12-31-$37.48M
2024-03-31-$54.6M
2023-12-31-$33.07M
2023-03-31-$31.86M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$147.78M
2024-12-31-$158.56M
2023-12-31-$141.22M
2022-12-31$10.67M
2021-12-31-$29.51M